University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center Trials

University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Chmielowski, Bartosz

IGNYTE-3, NCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs

Recruiting

400

Vusolimogene Oderparepvec, VO, RP1, Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Pembrolizumab, Keytruda, Single-agent chemotherapy

Replimune Inc.

Advanced Melanoma

01/29

08/34

SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting

2/3

360

Europe, Canada, US, RoW

Unesbulin, PTC596, Dacarbazine, DTIC, Placebo

PTC Therapeutics, PTC Therapeutics, Inc.

Leiomyosarcoma

06/24

IGNYTE, NCT03767348 / 2016-004548-12: Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

	Jan 2024 - Mar 2024 : Data from IGNYTE trial in combination with Opdivo for 2L melanoma
	From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
	Nov 2020 - Nov 2020: From P2 portion of P1/2 trial in combination with RP1 for solid tumors at SITC 2020
	Initial data from P1 portion of trial in combination with RP1 at SITC 2019
	Nov 2019 - Nov 2019: Initial data from P1 portion of trial in combination with RP1 at SITC 2019

Recruiting

340

Europe, US

RP1, nivolumab, Opdivo

Replimune Inc., Bristol-Myers Squibb

Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC

12/25

12/28

Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Recruiting

1/2

230

US, RoW

Phase 1b: APG-115+pembrolizumab, KEYTRUDA®

Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC

Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST)

12/24

03/25

XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting

1/2

189

XTX202

Xilio Development, Inc., Xilio Development, Inc

Advanced Solid Tumor

02/26

MUM, NCT03947385: Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

	Jan 2023 - Dec 2023: Data from P1/2 trial in combination with crizotinib for treatment of MUM
	Interim data from trial in combination with crizotinib for metastatic uveal melanoma
	Sep 2022 - Sep 2022: Interim data from trial in combination with crizotinib for metastatic uveal melanoma
	From trial in combination with darovasertib for uveal melanoma
	Dec 2021 - Dec 2021: From trial in combination with darovasertib for uveal melanoma

Recruiting

1/2

341

Canada, US, RoW

IDE196, Protein Kinase C (PKC) Inhibitor, Binimetinib, MEKTOVI, Crizotinib, XALKORI

IDEAYA Biosciences

Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors

12/26

03/27

KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Recruiting

400

Europe, US, RoW

KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib

Pierre Fabre Medicament

Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma

12/24

12/25

CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting

278

vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019

MacroGenics

Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma

04/25

06/25

PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Jul 2024 - Dec 2024 : P1 data from PERIO-01 trial for uveal melanoma liver metastases

Active, not recruiting

SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag

TriSalus Life Sciences, Inc.

Metastatic Uveal Melanoma in the Liver

09/24

01/25

KZR-261-101, NCT05047536: KZR-261 in Subjects With Advanced Solid Malignancies

Active, not recruiting

KZR-261, KZR-261 for Injection

Kezar Life Sciences, Inc.

Advanced/Metastatic Solid Tumor

12/25

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites